<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>ANTI-EPILEPTIC</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,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)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,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)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\13.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>ANTI-EPILEPTIC <a name='12:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	
<br>

<p>
<b>OVERVIEW:</b>
</p>

<p>
→ 3rd most common neurologic disease<br>
<ul>
<li>after cerebrovascular/Alzheimer diseases.</li>
</ul>
</p>

<p>
→ different types of seizures and syndromes [depending on site of action ] / several mechanisms<br>
<ul>
<li>motor cortex → abnromal movements  or generalized convulsion</li>
<li>parietal or occipital lobe → visual,audioty,olfactory halluginations</li>
</ul>
</p>

<p>
→ sudden : sudden, exescive , synchronous discharge of cerebral neurons
</p>

<p>
→ abnormal electrical activity<br>
<ul>
<li>may result in : — loss of consciousness — abnormal movement — atypical or odd behavour — disorted perception </li>
<li>— limited duration — reoccuarence is often  [ if untreated ]</li>
</ul>
</p>

<p>
<b>IDIOPATHIC OR SYMPTOMATIC SEIZURE:</b><br>
→ focal areas may be triggerd:<br>
<ul>
<li>alteration in blood gases</li>
<li>pH</li>
<li>electrolytes</li>
<li>blood glucose levels</li>
<li>changes in enviromental factors (sleep,alcochol etc)</li>
</ul>
→ neuro-imaging<br>
<ul>
<li>MRI ( mangetic resonance imaging)</li>
<li>PET (position-emission tomography)</li>
<li>SPECT (single-photon emission coherence tomography)</li>
</ul>
</p>

<br>

<p>
<ol type="A" start="1">
<li>IDIOPATHIC</li>
</ol>
→ no specific anatomic cause [ trauma/neoplasm]<br>
→ treated:<br>
<ul>
<li>chronically, with — antiseizures drugs or vagal nerve stimulation</li>
</ul>
</p>

<p>
B.SYMPTOMATAIC EPILEPSY<br>
→causes: — illictic drug use — tumor — head injury — hypoglycemia — menigeal infection — rapid withdraw of alcochol<br>
→ chronic treatment:<br>
<ul>
<li>antiseizure medications</li>
<li>vagal nerve stimulation </li>
<li>surgercy</li>
</ul>
</p>

<h3>CLASSIFICATION OF SEIZURES:</h3>

<p>
→  due  to : — site of origin — etiology — electrophysiological correlation  and clinical presentation<br>
→ classified into two main categories:<br>
<ul>
<li>Partial ( or focal )</li>
<li>Generalzied</li>
</ul>
<img src="./Pharmacology/pasted_image.png"><br>
A.PARTIAL<br>
→ only a portion of the brain<br>
<ul>
<li>part of the one lobe / of hemisphere</li>
</ul>
→ may progress to GENERALIZED Tonic-clonic seizures.<br>
<div style='padding-left: 30pt'>
1.Simple Partial
</div>
→ single locus of the brain<br>
→ does not spread <br>
→ not lose of consciousness<br>
→ sensory distortions<br>
→ may occur in any age<br>
<div style='padding-left: 30pt'>
2.Complex Partial
</div>
→ complex sensory hallucinations and mental disortions<br>
→ motor dysfunction [chewing,dirahhea,urination]<br>
→ conciousness is alerted<br>
→ simple partial may lead to complex and then spread to generalized convulsion<br>
→ may occur at any range<br>
B.GENERALIZED<br>
→ begin locally thought both hemispheres<br>
→ convulsive or non-convulsive<br>
→ immediate loss of conciousness<br>
<div style='padding-left: 30pt'>
1.Tonic-clonic
</div>
→ results in loss of conciousness   → lowed of tonic and clonic phases ( conitious contraction and relaxation)<br>
→ period of confusion and exhuastion ( due to depletion of glucose and energy stores)<br>
<div style='padding-left: 30pt'>
2.Absence
</div>
→ brief, abrupt, and self limiting loss of conciousness<br>
→ 3 to 5 years of age<br>
→ rapid-eye-blinking<br>
<div style='padding-left: 30pt'>
3.Myoclonic
</div>
→ short episodes of muscsle contractions for several minutes<br>
→ generally occur after wakening<br>
→ at any age [ usually puberty or earl adulthood ]<br>
<div style='padding-left: 30pt'>
4.Febrile seizures
</div>
→ young children <br>
→ high fever<br>
→ tonic-clonic convulsions of short period of time<br>
<div style='padding-left: 30pt'>
5.Statues-Epilecpticus
</div>
→ two or more seizures occur without recovery  of full conciousness between of them<br>
→ partial or generalized // convuslive or non convulsive<br>
→ life-threatening requires emergency treatment.
</p>

<h3>MECHANIMS OF ACTION OF ANTI-EPILECPTIC DRUGS:</h3>

<p>
→ blocking volatage-gated channels<br>
<ul>
<li>Na+2 or Ca+2</li>
</ul>
→ enhancing inhibitory γ-aminobutiric acid (GABA)-ergic impulses<br>
→ interefering with glutamate transmission<br>
→ some of them seems to have multiple targets within the CNS
</p>

<h1>DRUG CHOICE:</h1>

<p>
→ Based on:<br>
<ul>
<li>classification of the seizure</li>
<li>patient-specific variables (age,medical conditions,lifefstyle,personal preference)</li>
<li>characterstics of the drug ( toxicity , cost, interactions with other medications) </li>
</ul>
</p>

<p>
<img src="file:///C:/Users/nksse/OneDrive/%CE%A5%CF%80%CE%BF%CE%BB%CE%BF%CE%B3%CE%B9%CF%83%CF%84%CE%AE%CF%82/123.png"><br>
<img src="./Pharmacology/pasted_image002.png">
</p>

<br>

<h1>PRIMARY EPILECPTIC DRUGS:</h1>

<p>
<b>Older epileptics</b><br>
→ Carbamazepine      → Divalproex<br>
→ Ethosuxamide         → Phenobarbital<br>
→ Phenytoin               → Valporic acid
</p>

<p>
<b>"Second Generation"</b><br>
→ Felbamate			→ Ganbapetin 			→ Lacosamide			→ Lamotrigine<br>
→ Levetricaetam		→ Oxcarbazepine			→ Pregabalin				→Rufinamide<br>
→ Tiagabine			→ Topiramate 			→ Vigabatrin				→ Zonisamde
</p>

<p>
<div style='padding-left: 30pt'>
<b>A.BENZODIAZEPINES</b>
</div>
</p>

<p>
→ bidn to GABA inhibitory receptors <br>
<ul>
<li>reduce firing</li>
</ul>
→ Diazepam and Lorazepam<br>
<ul>
<li>most often used as an adjunctive therapy</li>
<li>myoclonic and partial and generalized tonic-clonic seizures</li>
</ul>
→ Lorazepam -= shorter half-life but stay in the brain longer than diazepam<br>
→ Diazepam rectal admin.
</p>

<p>
<div style='padding-left: 30pt'>
<b>B.CARBAMAZEPINE</b>
</div>
</p>

<p>
→ Carbamazepine<br>
<ul>
<li>↓ propagation of abnormal impulses in the brain by blocking sodium channels</li>
<li>inhibiting the genration of the repetitive action potentials in the epileptic focus and preventing the spread</li>
<li>partial /<i> generalized tonic-clonic seizures  trigeminal neuralgia </i>/// bipolar disorder</li>
<li>absorbed slowly and erratically following oral admin.</li>
</ul>
→ It induces its own drug metmabolism and has an active metabolite (epoxide)<br>
<ul>
<li>metabolite(epoxide) 25% of dose can be inhibited by drugs inhibit UGT → toxicity</li>
</ul>
→ CYP3A4 substrate<br>
<ul>
<li>inducer of — CYP1A2 — CYP2C and CYP3A+UGT enzymes</li>
</ul>
<img src="./Pharmacology/pasted_image003.png">
</p>

<p>
<div style='padding-left: 30pt'>
<b>C.ETHOSUXIMIDE</b>
</div>
</p>

<p>
→ ↓ propagation of abnormal electrical acitivity in the brain <br>
<ul>
<li>by inhibiting T-type calcium channels</li>
</ul>
→ primarly genarilzed absence seizures<br>
→ limited due to narrow spectrum of activity
</p>

<p>
<div style='padding-left: 30pt'>
<b>D.FELBAMATE</b>
</div>
</p>

<p>
→ broad-spectrum of anticonvulsant action<br>
→ multiple proposed mechanisms:<br>
<ol type="1" start="1">
<li>blocking voltage-dependent sodium channel</li>
<li>competing with the glycine-coagonist binding site on the N-methyl-D-asparate ( NMDA) glutamate receptor</li>
<li>blocking calclium channel</li>
<li>potentiating the action of GABA</li>
</ol>
→ it's an inhibitor of the drugs metabolized by CYP2C19 and b-oxidation and induce drugs metabolzied by CYP3A4.<br>
→ refractory epilepsies
</p>

<p>
<div style='padding-left: 30pt'>
<b>E.GABAPETIN</b>
</div>
</p>

<p>
→ analog of GABA<br>
<ul>
<li>does not act at GABA receptors</li>
<li>neither enhances GABA action</li>
<li>nor converted to GABA</li>
</ul>
→ precise mechanism is not known <br>
→ adjunct therapy for partial seizures //// posthreptic neuralgia<br>
→  nonlinear pharmacokinetics<br>
<ul>
<li>saturable transport system from the gut</li>
</ul>
→ not pind to plasma protein<br>
→ excrected unchanged through the kidneys<br>
→ be well tolarated by the elderly population with partial seizures
</p>

<p>
<div style='padding-left: 30pt'>
<b>F.LACOSAMIDE</b>
</div>
</p>

<p>
→ affects volatage-gated sodium channels<br>
<ul>
<li>stabilization of hyperexcitable neuronal membranes + inhibition of repetative neuronal firing</li>
</ul>
→ bind "collapsin" repsonse mediatior ( CRMP -2 ) <br>
→ adjuctive treatment of partial seizures<br>
→ produced euphoria as alazopram → labeled as control substance<br>
→ injectible formulation<br>
→ diziness, headache,fatigue.
</p>

<p>
<div style='padding-left: 30pt'>
<b>G.LAMOTRIGINE</b>
</div>
</p>

<p>
→ blocks sodium channel + high-voltage-dependent calcium channels<br>
→ wide variety of seizures — partial — generalized — typical absence seizures — Lennox-Gastaut syndorme<br>
→ approved for bipolar disorder<br>
→ metabolized primarly N-2 glucoronide through the UGT pathway.<br>
→ half-life ( 24-35 hours) is ↓ by enzyme inducing drugs( e.g.// carbamazepine,phenytoin ) <br>
<ul>
<li>↑ by greater than 50% with the addition of valporate.</li>
</ul>
→ high serum concentration = rashes <br>
→ well tolarated from elderly
</p>

<p>
<div style='padding-left: 30pt'>
<b>H.LEVETIRACETAM</b>
</div>
</p>

<p>
→ adjucnt therapy of — partial — generalized tonic-clonic seizures in childrens and adults<br>
→ exac moa is not known<br>
→ high affinity for a synaptic vesicle protein<br>
→ well absorbed orally and excrected in urine unchanged<br>
→ DOES not interact with CYP or UGT metabolism systeme.<br>
→ dizziness,sleep distrubances,headache,weakness
</p>

<p>
<div style='padding-left: 30pt'>
<b>I.OXCARBAZEPINE</b>
</div>
</p>

<p>
→ prodrug rapidly ↓ to the 10-monohydroxy metabolite<br>
<ul>
<li>responsible for anticonvulsant activity</li>
</ul>
→ blocks sodium channels<br>
<ul>
<li>preventing spread of the abnormal discharge</li>
</ul>
→ it's also moderate calcium channels<br>
→ less potent inducer of CYP3A4 and UGT than Carbamazepine<br>
→ nause,vomiting,headache and visual distrubances.
</p>

<p>
<div style='padding-left: 30pt'>
<b>J.PHENOBARBITAL</b>
</div>
→ enhancing the inhibitory effects of GABA-mediated neurons <br>
→ staticus epilepticus
</p>

<p>
<div style='padding-left: 30pt'>
<b>K.PHENYTOIN and FOSPHENYTOIN</b>
</div>
→ blocks voltage-gated sodium channels by selectively binding to the channel in the inactive state and slowing its rate of recovery<br>
→ very high concentrations also block voltage-dependent calcium channels [ release of monoaminergic neurotransmitters]<br>
→ partia — generalized tonic-clonic — status epilepticus<br>
→ 90% bound to albumin<br>
→ CYP2C and 3A families + UGT enzyme system<br>
→ zero-order pharmacokinetics<br>
→ small ↑ in daily doses can ↑ serum conc. → drug toxicity<br>
→givingal hyperplasia<br>
→ long-term use cause development of peripheral neuropathies and osteoporosis
</p>

<p>
→ Foshphenytoin<br>
<ul>
<li>produrg is rapidly converted into phenytoin</li>
<li>intramusculary</li>
</ul>
</p>

<p>
<div style='padding-left: 30pt'>
<b>L.PREGABALIN</b>
</div>
→ bind to a2-δ-site ( auxilary subunit of voltage-gated-calcium channels )<br>
→ inhibiting excitatory neurotranmitter release<br>
→ partial onest seizure → neuropathic pain associatedw with diabetic peripheral neuropathy → fibromyralgia<br>
→ 90% eliminated renally<br>
→ no indication of CYP involvment<br>
→ drowsiness,bullred vision,weight gain,peripheral edema.
</p>

<p>
<div style='padding-left: 30pt'>
<b>N.TIAGABINE</b>
</div>
→ blocks GABA uptake into presynaptic neurons → premetting more GABA to be available for receptor binding → enhance inhibotry activity<br>
→ ↓ number of partial onest seizures.<br>
→ binding to albumin and a1-acid-glycoprotein [greater than 95%]<br>
→ CYP3A family of enzymes<br>
→ fatigue,diziness,git upset<br>
→ has not approved for and should not be used for any other indication.
</p>

<p>
<div style='padding-left: 30pt'>
<b>O.TOPIRAMATE</b>
</div>
→ broad - spectrum actions<br>
<ul>
<li>blocks voltage-dependent sodium channel</li>
<li>↑ frequency of chloride channel opening — by binding to the GABAa receptor — </li>
<li>high voltage-calcium currents (L-type) are ↓ by  topiramate</li>
<li>it is carbonic anhydrase inhibitor and may act at glutamatme (NMDA) sites.</li>
<li>partial  and generalized epilepsy and migraine</li>
</ul>
→ eliminated renally and also has inactive meteabolites.<br>
→ inhibits CYP2C19 and induced by phenytoin and carbamazepine<br>
→ somnolence,weigh loss,paresthesias<br>
→ glaucoma,oligohidrosis,hyperthermia
</p>

<p>
<div style='padding-left: 30pt'>
<b>P.VALPORIC ACID AND DIVALPROEX</b>
</div>
→ available as a free acid<br>
→ Divalproex sodium converted to valproate when it reaches the git.<br>
<ul>
<li>developed to imprive gastrointestinal tolerance of valporic acid</li>
</ul>
→ multple-salt dosage forms and extended-release formulations<br>
→ induce sodium channel blockage<br>
<ul>
<li>blockage of GABA-transaminase</li>
<li>action at the T-type calcium channels</li>
</ul>
→ these mechanims provide:<br>
<ul>
<li>broad-spectrum of activity against seizures</li>
<li>partial and primarly seizures</li>
</ul>
→ inhibits CYP2C9,UGT,epoxide hydrolase systems<br>
→ bound to albumin (greater than 90)
</p>

<p>
<div style='padding-left: 30pt'>
<b>Q.VIGABATRIN</b>
</div>
→act as an irrevesible inhibitor of γ-aminobutyric acid transaminase (GABA-T_) is the enzyme responsible for metabolism of GABA.<br>
→ visual filed loss ranging fro mild to se vere<br>
→ SHARE PROGRAM pharmacies
</p>

<p>
<div style='padding-left: 30pt'>
<b>R.ZONISAMIDE</b>
</div>
→ sulfonamide derivative that has a broad spectrum of action neuronal system which involed in seizure generation<br>
→ blockage-of both voltage-gated sodium channel and T-type calcium currents<br>
→ limited amount of carbonic anhydrase activity<br>
→ metabolized by CYP3A4 isozyme<br>
→ may cause kidney stones,oligohidrosis
</p>

<h1>VAGAL NERVE STIMULATION</h1>

<br>

<p>
→ requires surgical implant of small pulse generator with a battery and a lead wire for stimulus<br>
→ treatment of depression
</p>

<p>
<img src="./Pharmacology/pasted_image004.png"><br>
<img src="./Pharmacology/pasted_image005.png"><br>
<img src="./Pharmacology/pasted_image006.png"><br>
<img src="./Pharmacology/pasted_image007.png">
</p>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>57.8kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>97.7kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image002.png'>pasted_image002.png</a></td><td>&nbsp;</td><td>207kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image003.png'>pasted_image003.png</a></td><td>&nbsp;</td><td>26.0kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image004.png'>pasted_image004.png</a></td><td>&nbsp;</td><td>333kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image005.png'>pasted_image005.png</a></td><td>&nbsp;</td><td>343kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image006.png'>pasted_image006.png</a></td><td>&nbsp;</td><td>362kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image007.png'>pasted_image007.png</a></td><td>&nbsp;</td><td>333kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
